Amicus Therapeutics, Inc.
LSE: 0HF9.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Bradley L. Campbell
- Employees
- 499
- Headquarters
- Philadelphia, United States
- IPO year
- 2018
- Market cap
- $5.3B
- Website
- https://amicusrx.com
Loading 0HF9…
Loading profile data…Frequently asked questions about 0HF9
What does Amicus Therapeutics, Inc. (0HF9.L) do?
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
Where does 0HF9.L trade?
Amicus Therapeutics, Inc. (0HF9.L) trades on the London Stock Exchange.
What sector is 0HF9.L in?
Amicus Therapeutics, Inc. (0HF9.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Amicus Therapeutics, Inc.?
Bradley L. Campbell is the chief executive officer of Amicus Therapeutics, Inc. (0HF9.L).
Where is Amicus Therapeutics, Inc. headquartered?
Amicus Therapeutics, Inc. is headquartered in United States.
Does 0HF9.L pay a dividend?
Amicus Therapeutics, Inc. (0HF9.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HF9.L go public?
Amicus Therapeutics, Inc. (0HF9.L) completed its initial public offering in 2018.